Original Investigation 

May 21, 2025

Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial

Tingting Ni, Xiaoxia Zhou, Shuguang Wu, et al

JAMA Surg. Published online May 21, 2025. doi:10.1001/jamasurg.2025.1299

Key Points

Question  Does cipepofol offer superior hemodynamic stability compared to propofol as an anesthesia induction agent?

Findings  In this randomized clinical trial involving 122 adults with aortic stenosis with anesthesia induced with either cipepofol or propofol, the cipepofol group exhibited a significantly smaller area under the curve for changes in mean arterial pressure relative to baseline compared to the propofol group.

Meaning  Cipepofol may be a safer alternative induction anesthetic for patients with severe aortic stenosis.

Abstract

Importance  Postinduction hemodynamic instability is a frequent complication among patients with severe aortic stenosis (AS). Using cipepofol as the anesthesia agent may reduce the incidence and severity of hemodynamic instability.

Objective  To assess whether cipepofol outperforms propofol in maintaining postinduction hemodynamic stability in patients with AS.

Design, Setting, and Participants  This single-center, randomized clinical trial was conducted from June 29, 2023, to July 8, 2024, at the Second Affiliated Hospital of Zhejiang University School of Medicine in China. Patients with AS scheduled for transcatheter aortic valve replacement (TAVR) were eligible for inclusion.

Interventions  Participants were randomized 1:1 to receive either cipepofol or propofol as anesthesia induction agents at equipotent doses.

Main Outcomes and Measures  The primary outcome was the area under the curve (AUC) of the mean arterial pressure (MAP) difference from baseline during the initial 15 minutes postinduction.

Results  A total of 124 patients with AS scheduled for TAVR were randomized into either the cipepofol group (n = 62) or the propofol group (n = 62). Of 124 patients randomized, 1 patient from each group was excluded due to ineligibility for the TAVR procedure, and data were analyzed for 122 patients (61 patients per group) based on the intention-to-treat principle. Among 122 total patients, mean (SD) age was 72.2 (5.0) years, and 53 patients (43.4%) were female. The cipepofol group exhibited a significantly smaller median (IQR) AUC (−8505.0 mm Hg · s [−12 402.8 to −5130.0]) compared with the propofol group (−13 189.0 mm Hg · s [−17 006.7 to −7593.3]; P < .001). Moreover, compared with the propofol group, the cipepofol group demonstrated a significantly lower incidence of postinduction hypotension (70.5% vs 88.5%; P = .01) and required a smaller median (IQR) dose of norepinephrine during the first 15 minutes postinduction (6.0 μg [0.0-10.0] vs 10.0 μg [5.0-20.0]; P = .006). Additionally, the 2 groups’ bispectral indices were comparable.

Conclusions and Relevance  In this randomized clinical trial, cipepofol provided superior hemodynamic stability as an induction agent compared to propofol at equipotent doses and similar anesthesia depths for patients with AS. Therefore, cipepofol could serve as an alternative induction agent to propofol for patients at high cardiovascular risk.

Trial Registration  ClinicalTrials.gov Identifier: NCT05881291